Happy Chinese New Year
Our New Year special promotion is available now.
Market News & Analysis
Glaxo pipeline cure still in question
Ken Odeluga February 6, 2019 10:00 PM
Glaxo’s ‘patent cliff’ has struck again.
The fourth quarter brought more progress for GlaxoSmithKline, the world no. 9 pharma by drug revenues, which is trying M&A to treat a chronic case of patent cliff. Glaxo shares erased losses from earlier on Wednesday, trading slightly higher after earnings were released. But the stock is now dithering. Investors are trying to make up their minds about how to react. Volumes and turnover rose year-on-year, lifting net profit to £1.22bn, above the £992m expected. New medicines helped, particularly Shingrix, a shingles vaccine, sales of which more than doubled to £221m. But the group also flagged a 5%-9% EPS drop in 2019. The forecast is pegged on a recently approved generic version of Advair, GSK’s best-selling drug, till recent years.
Part of GSK’s strategic blueprint for reducing development risk has also been aired in recent days with the tie-up with Germany’s Merck KGaA. The deal sees Glaxo acquire rights to a new-generation cancer immunotherapy. The cost is $4.2bn. Investors are aware that such outlays are necessities with pipelines maturing at alarming rates. But the market still winces on such news, including on Wednesday, when the group said that similar tie-ups “can be expected going forward”. These will eat up savings – seen at £500m a year – from splicing GSK’s consumer unit into Pfizer’s and spinning it off. Note the sharp negative reaction by Glaxo shares to the acquisition of Tesaro late last year.
Sure, GSK’s drive to tidy-up cash leeching developments continues. Seven such projects were ended between Q2 and the end of the recent quarter. But market tolerance for capital intensive remedies remains in question. With GSK flagging continued generic risk ahead the stock is unlikely to embark on much progress for the year just yet. After a 12% advance in 2018, it has since lagged even a sluggish FTSE with a rise of 2.6%.
This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.
GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.
In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.
GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.
Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit cityindex.com.sg for the complete Risk Disclosure Statement.
Cryptocurrencies are not legal tender currency and trading of derivatives on Cryptocurrencies are currently not covered under any regulatory regime in Singapore. Consequently, investors should be aware they do not have protection under the Securities and Futures Act (Cap. 289). Please ensure that you are fully aware of the risks.